Chan Henry Lee Sells 590 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 590 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total transaction of $103,447.88.

BeOne Medicines Price Performance

ONC opened at $270.15 on Friday. The business’s fifty day simple moving average is $295.32 and its 200 day simple moving average is $312.15. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $239.25 and a 52 week high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The stock has a market cap of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. As a group, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. EFG International AG bought a new position in BeOne Medicines during the 4th quarter worth approximately $25,000. Leonteq Securities AG bought a new stake in BeOne Medicines in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. bought a new stake in BeOne Medicines in the second quarter valued at approximately $35,000. CWM LLC boosted its stake in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at approximately $61,000. Institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

ONC has been the subject of several research reports. Wall Street Zen lowered BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 price target on the stock. Royal Bank Of Canada boosted their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.